Should I buy or sell X4 Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XFOR shares. View XFOR analyst ratings or view top-rated stocks .

What is X4 Pharmaceuticals' stock price target for 2024?

2 equities research analysts have issued 1-year price objectives for X4 Pharmaceuticals' stock. Their XFOR share price targets range from $1.00 to $5.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 138.1% from the stock's current price. View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts .

How have XFOR shares performed in 2024?

X4 Pharmaceuticals' stock was trading at $0.8385 at the beginning of the year. Since then, XFOR shares have increased by 50.3% and is now trading at $1.26. View the best growth stocks for 2024 here .

When is X4 Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our XFOR earnings forecast .

How were X4 Pharmaceuticals' earnings last quarter?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) released its earnings results on Thursday, March, 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.05.

What ETFs hold X4 Pharmaceuticals' stock?

ETFs with the largest weight of X4 Pharmaceuticals (NASDAQ:XFOR) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) . Simplify Propel Opportunities ETF (SURI) .

What other stocks do shareholders of X4 Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX) , Ovid Therapeutics (OVID) , Pfizer (PFE) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Viking Therapeutics (VKTX) , AbbVie (ABBV) , Flexion Therapeutics (FLXN) , Heat Biologics (HTBX) and SCYNEXIS (SCYX) .

How do I buy shares of X4 Pharmaceuticals?

Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XFOR

X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free XFOR Stock Alerts

$1.26

+0.06 (+5.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.18
▼
$1.31
50-Day Range: $0.84
▼
$1.47
52-Week Range: $0.57
▼
$2.58

Volume: 3.06 million shs
Average Volume: 2.17 million shs
Market Capitalization: $211.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Get X4 Pharmaceuticals alerts:

X4 Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 138.1% Upside
$3.00 Price Target
Short Interest: Healthy
7.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.77
Based on 2 Articles This Week
Insider Trading: Selling Shares
$170,428 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.47) to ($0.46) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.27 out of 5 stars

Medical Sector

127th out of 911 stocks

Biological Products, Except Diagnostic Industry

13th out of 150 stocks

3.3

Analyst's Opinion

Consensus Rating
X4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
X4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
7.34% of the outstanding shares of X4 Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
X4 Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in X4 Pharmaceuticals has recently decreased by 13.29%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
X4 Pharmaceuticals does not currently pay a dividend.
Dividend Growth
X4 Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
X4 Pharmaceuticals has received a 71.51% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for mental health" and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for X4 Pharmaceuticals is -0.85.

3.2

News and Social Media Coverage

News Sentiment
X4 Pharmaceuticals has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 15 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.
MarketBeat Follows
5 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $170,428.00 in company stock.
Percentage Held by Insiders
Only 1.08% of the stock of X4 Pharmaceuticals is held by insiders.
Percentage Held by Institutions
72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.47) to ($0.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of X4 Pharmaceuticals is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of X4 Pharmaceuticals is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
X4 Pharmaceuticals has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About X4 Pharmaceuticals Stock (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

XFOR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XFOR Stock News Headlines

April 18, 2024 | seekingalpha.com

X4 Pharmaceuticals: PDUFA Excitement Ahead

April 17, 2024 | msn.com

X4 Pharmaceuticals (XFOR) Price Target Increased by 8.75% to 3.62

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 11, 2024 | finance.yahoo.com

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns

April 2, 2024 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 2, 2024 | finance.yahoo.com

XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…

April 1, 2024 | globenewswire.com

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

March 23, 2024 | seekingalpha.com

X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects

March 22, 2024 | insidermonkey.com

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript

March 22, 2024 | finance.yahoo.com

Q4 2023 X4 Pharmaceuticals Inc Earnings Call

March 21, 2024 | investorplace.com

XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023

March 21, 2024 | finance.yahoo.com

X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results

March 21, 2024 | globenewswire.com

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

March 12, 2024 | globenewswire.com

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

March 9, 2024 | finance.yahoo.com

XFOR Jan 2026 1.000 call

March 9, 2024 | finance.yahoo.com

XFOR Apr 2024 1.500 call

March 2, 2024 | investing.com

X4 Pharmaceuticals Inc (XFOR)

March 1, 2024 | globenewswire.com

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 24, 2024 | benzinga.com

X4 Pharmaceuticals Stock (NASDAQ:XFOR), Short Interest Report

February 23, 2024 | finance.yahoo.com

XFOR Mar 2024 1.500 put

February 22, 2024 | benzinga.com

X4 Pharmaceuticals Stock (NASDAQ:XFOR) Insider Trades

February 19, 2024 | thestreet.com

X4 Pharmaceuticals Inc.

February 17, 2024 | finance.yahoo.com

XFOR May 2024 1.500 call

February 17, 2024 | finance.yahoo.com

XFOR Jan 2025 1.500 call

February 16, 2024 | finance.yahoo.com

XFOR Mar 2024 1.000 put

See More Headlines

Receive XFOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:XFOR
CUSIP: N/A
CIK: 1501697
Web: www.x4pharma.com
Phone: (857) 529-8300
Fax: N/A
Employees: 93
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $5.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +138.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-101,170,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -170.10%
Return on Assets: -65.44%

Debt

Debt-to-Equity Ratio: 1.07
Current Ratio: 5.34
Quick Ratio: 5.34

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.31 per share
Price / Book: 4.06

Miscellaneous

Outstanding Shares: 167,940,000
Free Float: 166,124,000
Market Cap: $211.60 million
Optionable: Optionable
Beta: 0.49

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Paula Ragan Ph.D. (Age 54)
CEO, President & Director
Comp: $963.58k
Mr. Adam S. Mostafa (Age 43)
CFO, Treasurer & Corporate Secretary
Comp: $699.18k
Dr. Mary DiBiase Ph.D. (Age 63)
Chief Operating Officer
Comp: $661.59k
Dr. Richard Peters M.D. (Age 61)
Ph.D., Founder
Dr. Renato T. Skerlj Ph.D.
Founder
Dr. Keith T. Flaherty M.D. (Age 53)
Founder & Member of Corporate Advisory Board
Dr. Arthur Taveras Ph.D. (Age 60)
Chief Scientific Officer
Dr. Glenn Schulman M.P.H.
Pharm. D., Pharm.D., Vice President of Investor Relations & Corporate Communications
Dr. Robert David Arbeit (Age 76)
Senior Vice President of Clinical Development and Translational Research
Mr. Mark Baldry M.B.A. (Age 60)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XFOR Stock Analysis - Frequently Asked Questions

Should I buy or sell X4 Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XFOR shares.
View XFOR analyst ratings or view top-rated stocks.
What is X4 Pharmaceuticals' stock price target for 2024?: 2 equities research analysts have issued 1-year price objectives for X4 Pharmaceuticals' stock. Their XFOR share price targets range from $1.00 to $5.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 138.1% from the stock's current price.
View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts.
How have XFOR shares performed in 2024?: X4 Pharmaceuticals' stock was trading at $0.8385 at the beginning of the year. Since then, XFOR shares have increased by 50.3% and is now trading at $1.26.
View the best growth stocks for 2024 here.
When is X4 Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our XFOR earnings forecast.

How were X4 Pharmaceuticals' earnings last quarter?: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) released its earnings results on Thursday, March, 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.05.
What ETFs hold X4 Pharmaceuticals' stock?: ETFs with the largest weight of X4 Pharmaceuticals (NASDAQ:XFOR) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).Simplify Propel Opportunities ETF (SURI).
What other stocks do shareholders of X4 Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX).
How do I buy shares of X4 Pharmaceuticals?: Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XFOR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis

X4 Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About X4 Pharmaceuticals Stock (NASDAQ:XFOR)

XFOR Stock Price History

XFOR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

XFOR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™